Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 20 or older, regardless of gender.~* Receiving stable maintenance hemodialysis 3 times a week.~* Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.~Exclusion Criteria:~* Patients having history of a pronounced brain / cardiovascular disorder.~* Patients having severe gastrointestinal disorders.~* Patients having severe hepatic disorders.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PA21 (Type: EXPERIMENTAL): None
- Sevelamer hydrochloride (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).